Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients
- 2 December 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Abstract
Neutralizing autoantibodies against type I interferons are a risk factor for multiple severe viral diseases. The timely detection of these autoantibodies remains an unmet need. We hypothesized that paradoxically low expression of type I IFN-induced CD169/SIGLEC1 expression analyzed by flow cytometry may allow rapid screening for the presence of these autoantibodies. In a prospective cohort study, we quantified monocytic CD169/SIGLEC1 expression and neutralizing autoantibodies against type I interferons in 808 patients who presented to the emergency room with signs of acute infections during the second wave of the SARS-CoV-2 pandemic in Germany in 2021. In patients, elevated CD169/SIGLEC1 (>2400 mAb/cell) demonstrated a negative predictive value of 100% for the detection of neutralizing autoantibodies against type I interferons. Low CD169/SIGLEC1 (50 mg/L exhibited a positive predictive value of 70% for neutralizing autoantibodies against type I interferons. We further compared the adjusted odds ratio for mortality in patients with these autoantibodies to that in patients without autoantibodies against type I interferons. Neutralizing autoantibodies against type I interferons were associated with a worse clinical outcome, independent of SARS-CoV-2 infection, implying their presence is a risk factor for a worse general outcome.Keywords
Funding Information
- Labor Berlin
- Stiftung Charité
- Deutsche Forschungsgemeinschaft
- German Ministry of Education and Research
- German Ministry of Health
- German Innovations Funds
- Berlin University Alliance
- Scientific Institute of the Statutory Health Insurance Physicians
- Roche Diagnostics
- Health Care Research
- German Ministry of Education and Research
- German Ministry of Health
- German Innovations Funds
This publication has 71 references indexed in Scilit:
- Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in ShanghaiJournal of Clinical Immunology, 2024
- Genetic and Functional Identifying of Novel STAT1 Loss-of-Function Mutations in Patients with Diverse Clinical PhenotypesJournal of Clinical Immunology, 2022
- Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodiesJournal of Clinical Immunology, 2022
- Life-Threatening Enterovirus 71 Encephalitis in Unrelated Children with Autosomal Dominant TLR3 DeficiencyJournal of Clinical Immunology, 2022
- Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 DeficiencyJournal of Clinical Immunology, 2021
- Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2Journal of Clinical Immunology, 2021
- Pathogenic TLR3 Variant in a Patient with Recurrent Herpes Simplex Virus 1–Triggered Erythema MultiformeJournal of Clinical Immunology, 2020
- Identification of an IRF3 variant and defective antiviral interferon responses in a patient with severe influenzaEuropean Journal of Immunology, 2019
- Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic DiseasesArthritis & Rheumatology, 2016
- Novel STAT1 Alleles in a Patient with Impaired Resistance to MycobacteriaJournal of Clinical Immunology, 2010